Drug intelligence / Profile preview

LPT-101

Development stage: Preclinical
Lead developer: LitePharmTech
Modality: Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

LPT-101 is a next-generation small molecule photosensitizer being developed by LitePharmTech for the treatment of cancer via photodynamic therapy (PDT). As a new chemical entity (NCE) based on Chlorin e6 (Ce6), LPT-101 is designed to localize within tumor tissues. Upon activation by a specific wavelength of light, the molecule facilitates the conversion of molecular oxygen into reactive oxygen species (ROS), primarily singlet oxygen. This process triggers localized oxidative damage to cellular structures, including proteins and lipids, resulting in tumor cell apoptosis, necrosis, and the collapse of tumor-associated vasculature. LPT-101 is currently in preclinical development.

Other names: Chlorin e6

Beyond the preview

Go deeper on LPT-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LPT-101.

Explore the full profile